Catalyst continues to actively enroll patients in the SUMMIT study, an open-label five-year follow-up study designed to evaluate the long-term clinical safety profile of AGAMREE, including potential ...

As ammonia gains attention as a next-generation energy source capable of overcoming the limits of hydrogen storage and transport, KAIST and a joint research team have developed fuel cell technology ...

A research team from Sungkyunkwan University and Kyungpook National University has developed a non-precious ...

The move marks Italy’s Angelini Pharma’s entry into the U.S. market.

Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst's operating results ...